Overexpression of the PPAR‑γ protein in primary Ta/T1 non‑muscle‑invasive urothelial carcinoma

Peroxisome proliferator‑activated receptor‑γ(PPAR‑γ) is a well‑known nuclear receptor that is activated in the nucleus to regulate several transcription factors. Its expression patterns have been examined in various types of cancer. The present study investigated the expression patterns of PPAR‑γ in non‑muscle‑invasive urothelial carcinoma. The expression rates of PPAR‑γ, p53 and Ki‑67 were compared to determine whether PPAR‑γ may be considered as an immunobiomarker for bladder cancer. The intensity and extent of PPAR‑γ expression were evaluated in 79 cases of non‑muscle‑invasive urothelial carcinoma (30 cases of papillary carcinoma low‑grade, 30 cases of high‑grade and 19 cases of carcinoma in situ) and 30 non‑malignant cases. The nuclear overexpression of PPAR‑γ was frequently observed in non‑muscle‑invasive urothelial carcinoma (63/79 cases) but was rarely detected in non‑malignant cases (2/30 cases). The histological proliferation types of non‑muscle‑invasive urothelial carcinoma revealed that PPAR‑γ was more frequently overexpressed in papillary carcinoma (54/60 cases) than in carcinoma in situ (9/19 cases). Immunohistochemical staining demonstrated that PPAR‑γ was more useful as an immunobiomarker than p53 or Ki‑67 (diagnostic odds ratios; 55.13, 16.82 and 11.13, respectively). In summary, this study demonstrated that the expression patterns of PPAR‑γ were associated with histological proliferation type and that PPAR‑γ was expressed in the nuclei of papillary carcinoma cells. These findings suggested that immunohistochemical staining for PPAR‑γ may be used to comprehensively detect non‑muscle‑invasive urothelial carcinoma.

source:https://www.spandidos-publications.com/pages/mco/info_for_authors

収集根拠 : 博士論文（自動収集）
資料形態 : テキストデータ
コレクション : 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
Peroxisome proliferator‑activated receptor‑γ(PPAR‑γ) is a well‑known nuclear receptor that is activated in the nucleus to regulate several transcription factors. Its expression patterns have been examined in various types of cancer. The present study investigated the expression patterns of PPAR‑γ in non‑muscle‑invasive urothelial carcinoma. The expression rates of PPAR‑γ, p53 and Ki‑67 were compared to determine whether PPAR‑γ may be considered as an immunobiomarker for bladder cancer. The intensity and extent of PPAR‑γ expression were evaluated in 79 cases of non‑muscle‑invasive urothelial carcinoma (30 cases of papillary carcinoma low‑grade, 30 cases of high‑grade and 19 cases of carcinoma in situ) and 30 non‑malignant cases. The nuclear overexpression of PPAR‑γ was frequently observed in non‑muscle‑invasive urothelial carcinoma (63/79 cases) but was rarely detected in non‑malignant cases (2/30 cases). The histological proliferation types of non‑muscle‑invasive urothelial carcinoma revealed that PPAR‑γ was more frequently overexpressed in papillary carcinoma (54/60 cases) than in carcinoma in situ (9/19 cases). Immunohistochemical staining demonstrated that PPAR‑γ was more useful as an immunobiomarker than p53 or Ki‑67 (diagnostic odds ratios; 55.13, 16.82 and 11.13, respectively). In summary, this study demonstrated that the expression patterns of PPAR‑γ were associated with histological proliferation type and that PPAR‑γ was expressed in the nuclei of papillary carcinoma cells. These findings suggested that immunohistochemical staining for PPAR‑γ may be used to comprehensively detect non‑muscle‑invasive urothelial carcinoma.
source:https://www.spandidos-publications.com/pages/mco/info_for_authors